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Edited by Lukas HuberAbstract In humans, many responses to hypoxia including
angiogenesis and erythropoiesis are mediated by the a/b-hetero-
dimeric transcription factor hypoxia inducible factor (HIF). The
stability and/or activity of human HIF-1a are modulated by
post-translational modiﬁcations including prolyl and asparaginyl
hydroxylation, phosphorylation, and reportedly by acetylation of
the side-chain of Lys532 by ARD1 (arrest defective protein 1
homologue), an acetyltransferase. Using puriﬁed recombinant
human ARD1 (hARD1) we did not observe ARD1-mediated
N-acetylation of Lys532 using fragments of HIF-1a. However,
recombinant hARD1 from Escherichia coli was produced with
partial N-terminal acetylation and was observed to undergo slow
self-mediated N-terminal acetylation. The observations are con-
sistent with the other data indicating that hARD1, at least alone,
does not acetylate HIF-1a, and with reports on the N-terminal
acetyltransferase activity of a recently reported heterodimeric
complex comprising hARD1 and N-acetyltransferase protein.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transcription1. Introduction
In many animals, cellular responses to reduced oxygen con-
centration (hypoxia) are mediated by an a/b-heterodimeric
transcription factor, hypoxia inducible factor (HIF) [1]. Under
hypoxic conditions, HIF binds to response elements linked to
an array of genes related to the hypoxic response including, in
humans, those associated with angiogenesis (vascular endothe-
lial growth factor, VEGF) and erythropoiesis (erythropoietin,
EPO). HIF-1b is a constitutively nuclear protein, but levels of
HIF-1a are low under normal oxygen concentrations (nor-
moxia) and rise in response to hypoxia [1].
Recent studies have identiﬁed mechanisms by which both
the transcriptional activity and levels of HIF-1a are regulated
by molecular oxygen. Post-translational trans-4-hydroxylation
of either of two proline residues, that form part of consensusAbbreviations: HIF, hypoxia inducible factor; ARD1, arrest defective
protein 1; NATH, N-acetyltransferase (human); EPO, erythropoietin;
PHD, prolyl hydroxylase; FIH, factor inhibiting HIF; ACTH, adre-
nocorticotropic hormone; VEGF, vascular endothelial growth factor;
HRE, hypoxic response element
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of human HIF-1a, is suﬃcient to target HIF-1a to the von
Hippel–Lindau protein [2–4], which in turn recruits a ubiquitin
ligase, that mediates proteasomal destruction. In humans,
hydroxylation of an asparaginyl residue in the C-terminal tran-
scriptional activation domain of HIF-1a ablates the interac-
tion between HIF-1a and the p300 protein, thereby blocking
transcription of HIF-1a-regulated genes [5]. Four hydroxylases
have been identiﬁed that catalyse these post-translational mod-
iﬁcations of human HIF-1a: three prolyl-hydroxylases
(PHD1–3) [6,7] and an asparaginyl hydroxylase, factor inhibit-
ing HIF (FIH) [8,9].
In addition to hydroxylation, HIF-1a polypeptides undergo
other post-translational modiﬁcations and studies have identi-
ﬁed sites of phosphorylation, ubiquitylation, and sumoylation
[10–13]. Such modiﬁcations are of interest from the perspective
of understanding the oxygen dependent regulation of HIF as
they could enhance or reduce the transcriptional activity of
HIF system even though they are not necessarily themselves
direct redox transformations [14].
Jeong et al. have also reported that regulation of HIF-1a oc-
curs via a mechanism involving acetylation of the side-chain of
Lys532 of human HIF-1a, catalysed by hARD1 [15] [human
analogue of yeast ARD1 protein; also known as ARD1 (from
arrest defective protein 1) or ARDH]. In yeast, ARD1 forms a
heterodimer with NAT1 (N-acetyltransferase protein); the
resultant complex, (NatA) is anchored to the ribosome and
catalyses N-terminal acetylation of nascent polypeptides [16].
The murine NAT complex (composed of mNAT and mARD)
is important in neuronal development as it is highly expressed
in areas of cell division but down regulated in areas of cell pro-
liferation [17]. Formation of an analogous complex between
hARD1 and hNAT1 in human cells has been observed using
coimmunoprecipitation coupled to mass spectrometric analysis
[18]. The reported observations of Jeong et al. with HIF-1a are
potentially important as they imply that hARD1 is the ﬁrst
identiﬁed acetyltransferase to possess both an N-terminal ace-
tyltransferase (in complex with N-acetyltransferase (human);
NATH) and (by itself) lysyl side-chain acetyltransferase
activity.
We have studied the acetyltransferase activity of puriﬁed re-
combinant hARD1 using fragments of HIF-1a and also a frag-
ment of the peptide hormone ACTH (adrenocorticotropic
hormone) as potential substrates. ACTH was chosen in the ab-
sence of a clearly deﬁned hARD1 substrate as a representative
known substrate of NatA which is acetylated on its N-terminal
serine residue [18]. Although we did not observe acetylation of
Lys532 of HIF-1a fragments or any acetylation of ACTHblished by Elsevier B.V. All rights reserved.
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tion reaction at the N-terminus of hARD1 takes place both
on (His)6-tagged hARD1 and the resulting (His)6-tag-derived
residues at the N-terminus after cleavage of the (His)6-tag.
N-Terminal acetylation of wild-type hARD1 was not
observed, consistent with the predicted speciﬁcity of the
ARD1-containing NatA complexes in yeast [19]. The results
are consistent with studies that question the conclusions of
Jeong et al. that hARD1 is involved in the regulation of
HIF-1a activity [20,21].2. Materials and methods
2.1. Cloning, overexpression and puriﬁcation of recombinant hARD1
The DNA sequence encoding the hARD1 protein was ampliﬁed by
PCR from a construct donated by Prof. C. W. Pugh, (Wellcome Trust
Centre for Human Genetics, Oxford University) as an EcoRI(NdeI/
BamHI)HindIII fragment using the primers 5 0-CACCGGTGAAT-
TCCATATGAACATCCGCAAT-30 (sense) and 5 0-TGGTGGAAG-
CTTGGATCCCTAGGAGGCTGAGTC-3 0 (antisense), and ligated
into the pMAL-c2x-1 vector (New England Biolabs). The hARD1 gene
was then excised as an NdeI/BamHI fragment using the appropriate
restriction enzymes and ligated into the pET28a(+) vector (Novagen).
The pET28a/hARD1 construct was transformed into BL21(DE3) Esch-
erichia coli cells for protein expression, andthe resulting (His)6-hARD1
was puriﬁed with His-Bind resin (Novagen). When appropriate the
(His)6-tag was cleaved by overnight incubation with thrombin at
4 C at a ratio of 2.5% (w/w) and further puriﬁcation was achieved
using a Superdex-S75 column (320 ml) equilibrated with 100 mM
Tris–HCl, pH 7.5.2.2. Cloning, overexpression and puriﬁcation of HIF substrate fragments
A construct encoding the HIF504–553 fragment in a modiﬁed version
of the pGEX-6P1 vector was donated by Prof. C. W. Pugh, Wellcome
Trust Centre for Human Genetics, Oxford University. The hif401–603
fragment was cloned as a SacII/AscI fragment and ligated into a
modiﬁed version of the pGEX-6P1 vector. Primers were 5 0-TGG-
GGCCCGCGGATGGCCCCAGCCGCTGGAGACACA-3 0 (sense)
and 5 0-GCTGGAGGCGCGCCATCCTGGAATCATGTAACTGTG-
3 0 (antisense). Constructs were transformed into BL21(DE3) E. coli
cells and overexpressed as GST fusion proteins, and the resulting
proteins were puriﬁed as previously reported using glutathione sephar-
ose 4B resin (Amersham Biosciences) [9].
2.3. Analysis of acetyltransferase activity
Liquid chromatography–mass spectrometry (LC/MS) assays were
performed using a Waters 600 high performance liquid chromatograph
connected to a Micromass ZMD electrospray-quadrupole mass spec-
trometer operated in the positive ion mode. The HPLC was equipped
with a Jupiter 5m C4 300A column (250 mm · 1.60 mm). The ﬁnal
concentration of substrate was 200 nM, the concentration of enzyme
was 200 nM and the concentration of AcCoA varied between
200 nM and 2 lM. The protein was either assayed in a total sample
volume of 50 ll, then precipitated with an equal volume of MeOH
and 80 ll of the resulting sample was injected, or a total sample volume
of 100 and 80 ll was injected with no precipitation step. [Controls were
carried out under identical conditions but with hARD1 omitted and/or
AcCoA omitted.] The solvent system used was: A: 95% H2O/5% aceto-
nitrile/0.1% HCOOH, B: 5% H2O/95% acetonitrile/0.1% HCOOH,
with the column equilibrated in 95% A before injection. The gradient
was programmed as follows: 0–5 min 5% B isocratic; 5–35 min 5–95%
B; 35–38 min 95% B isocratic; 38–40 min 95–5% B; 40–55 min 5% B
isocratic.
For tryptic digestions, the protein of interest was isolated by SDS–
PAGE, stained with Coomassie Blue stain, excised and destained using
100 ll of destain solution (50 mM ammonium bicarbonate in 50% ace-
tonitrile) with agitation until the Coomassie stain was completely re-
moved. The excised gel pieces were then treated with 80% aqueous
acetonitrile for 20 min with no agitation before the acetonitrile was re-
moved by pipette and the gel dehydrated by heating under reducedpressure for 30 min. Tryptic digestion was performed overnight using
50 ll of 20 ng/ll trypsin in 20 mM ammonium bicarbonate at 37 C.
The resulting supernatant was removed and peptides were extracted
from the gel using 50 ml of 0.1% TFA in 50% acetonitrile (twice).
These extracts were then combined and evaporated to dryness in a in
vacuo before being reconstituted in 10 ll of 0.1% CF3CO2H immedi-
ately prior to use.
ESI/MS and ESI/MS/MS analyses were conducted using a Micro-
mass (now Waters) Q-TOFmicro mass spectrometer. The capillary
voltage was set to 3 kV and the sample and extractor cone voltages
to 35 and 7.7 V, respectively. Nitrogen was used as the nebuliser and
desolvation gases, and argon was employed for MS/MS collision in-
duced dissociation. For LC/ESI-MS (and LC/ESI-MS/MS) the instru-
ment was coupled to an Agilent 1100 capillary LC system equipped
with a Phenomenex Jupiter C4 (150 mm · 0.5 mm) column using a gra-
dient of water (0.1% formic acid) A and acetonitrile (0.1% formic acid)
B as the mobile phase. The gradient was programmed as follows: 0–
5 min 5% B isocratic; 5–30 min 5–43% B; 30–50 min 43–95% B.
For autoradiography analyses, the procedure of Ito [22] was fol-
lowed. [1-14C]-AcCoA (50 nCi) was incubated with enzyme (10 lg)
and substrate (10 lg) and made up to a ﬁnal volume of 10 ll with reac-
tion buﬀer as described. The pH of the incubations was varied in one
set of assays; subsequent self-acetylation studies were performed at pH
10. Controls were run with several proteins that contained an N-termi-
nus consisting of a glycyl, serinyl or threoninyl residue, under the same
conditions as those used for hARD1 and HIF substrates. The control
proteins were FIH [9], HIF530–698, open reading frames 2 [23], 15 and
16 from the clavulanic acid biosynthesis pathway (unpublished data),
and phytanoyl coenzyme A hydroxylase [24], and were donated by
D. Lancaster, A. Hardy, Dr. M. Caines and Dr. T. Searls, respectively
(Chemistry Research Laboratory, Oxford University).3. Results
3.1. Production of recombinant hARD1
The DNA sequence encoding hARD1 was prepared as an
NdeI/BamHI fragment and ligated into the pET28a(+) vector
(as used by Jeong et al. [15]) in order to produce N-terminally
(His)6-tagged hARD1. The N-terminus of the resultant protein
was GSSHHHHHHSSGLVPRGSHMNIR with the sequence
of the hARD1 beginning from the 20th residue (underlined).
ESI-MS analysis conﬁrmed the presence of material of the pre-
dicted mass for (His)6-hARD1 lacking the N-terminal methio-
nine residue (predicted with N-terminal methionine 28622 Da,
without 28492 Da; observed mass 28496 Da). However, there
was also a further peak apparent in the ESI-MS with a mass
increase of 42 Da (Fig. 1, see below). Unoptimised cleavage tri-
als with thrombin of the (His)6-tag of the (His)6-ARDH, at
4 C, room temperature and 37 C led to low yields of cleaved
enzyme and so initial assays were performed using (His)6-
hARD1.
3.2. Evaluation of HIF fragments and ACTH as substrates for
hARD1
The acetyltransferase activity of (His)6-hARD1 was initially
investigated in two ways: ﬁrstly, the HIF504–553 fragment was
incubated with (His)6-hARD1 and AcCoA and studied by
LC/MS; secondly, HIF504–553 was treated with (His)6-hARD1
and [1-14C]-AcCoA and studied by [14C]-autoradiography.
During analysis by LC/MS, the unacetylated HIF fragment
(observed as the [M + 8H]8+ charge state at m/z 947, and the
[M + 7H]7+ charge state at m/z 1082) was clearly visible in
the negative control (without enzyme) and also in the (His)6-
hARD1 containing incubation. There was no evidence of
any acetylated HIF504–553 in the enzyme-containing assay
(Fig. 2). The [M + 8H]8+ charge state of HIF504–553 did contain
Fig. 1. ESI-MS analysis of (His)6-tagged hARD1. The peak at
28496 Da corresponds to the unacetylated hARD1 (predicted value
28492 Da) whereas that at 28538 Da corresponds to a mass increase of
42 Da and addition of an acetyl group. Other peaks correspond to
sodium and potassium adducts.
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would be consistent with methionine oxidation (the fragment
contains one methionine residue). However, the presence of
these minor peaks in both the assay mixture and the control
incubation demonstrated that they were not introduced by a
(His)6-hARD1-mediated process. Autoradiographic analysis
also did not lead to any evidence for (His)6-hARD1-mediated
acetylation of HIF504–553 (Fig. 3A). Due to the failure of
HIF504–553 to act as a substrate, HIF401–603 (reported as a sub-
strate by Jeong et al.) was expressed as N-terminal GST fusion
protein and used in partially puriﬁed form to investigate
whether it acts as a substrate for hARD1 by [14C]-autoradiog-
raphy (Fig. 3B). Again no evidence for acetylation of the HIF
fragment was observed.
A peptide corresponding to the ﬁrst 24 N-terminal residues
of ACTH (adrenocorticotropic hormone; predicted mass
2933 Da) was incubated with (His)6-hARD1 and AcCoA to
investigate the potential N-terminal acetyltransferase activity
of hARD1. LC/MS analyses of the incubation revealed the
peptide visible as the +3 and +4 charge states (at m/z 979
and 735, respectively) in its unacetylated form in both the as-
say incubation and in a no enzyme negative control (data
not shown).
3.3. N-Terminal-acetylation of (His)6-tag derived residues on
hARD1
During studies investigating the acetyltransferase activity of
(His)6-hARD1 using HIF-1a fragments, a radioactive band
corresponding to the position of hARD1 was observed by
SDS–PAGE autoradiography, implying that a radioactive ace-
tyl group had been transferred onto (His)6-hARD1 itself
(Fig. 3). As the N-terminal acetyltransferase activity of yeast
NatA complex is reported to be selective for Ala, Gly, Ser
and Thr residues [19], and the N-terminal residue of (His)6-
hARD1 was Gly (after N-terminal Met processing, the
sequence of the ﬁrst 9 residues of the protein wasGSSHHHHHH) the possibility of (His)6-hARD1 self-acetyla-
tion was investigated.
Directly after puriﬁcation by Ni-aﬃnity chromatography,
the deconvoluted ESI-MS of (His)6-hARD1 displayed a minor
peak at 28496 Da consistent with loss of the N-terminal Met
residue of the (His)6-tag with no modiﬁcation. However, the
major species present had a mass of 28538 Da and corre-
sponded to a mass shift of +42 Da consistent with partial acet-
ylation (Fig. 1). Further minor peaks at higher mass were
attributed to sodium and potassium adducts. Identiﬁcation
of the putative acetylation site was achieved using tryptic
digestion and LC/MS analysis, which clearly identiﬁed the site
of acetylation as the N-terminal peptide derived from the
(His)6-tag of the (His)6-hARD1. No evidence for acetylation
elsewhere on the (His)6-hARD1 was accrued.
The N-terminal tryptic peptide had a predicted mass of
1767.8 Da (monoisotopic) and gave by LC/ESI-MS the +2
and +3 charge states (m/z 885.0 and 590.4, respectively). The
acetylated form of the peptide had a predicted mass of
1809.8 Da and was visible as the +2 and +3 charge states
(m/z 906.5 and 604.3, respectively). MS/MS analysis was per-
formed on the ions at m/z 590.4 and 604.3 to conﬁrm the se-
quence of the acetylated and unacetylated peptides and to
assign the position of acetylation (Fig. 4).
To eliminate the possibility that the observed N-terminal
acetylation site of (His)6-hARD1 was not due to a self-acetyla-
tion but was occurring through N-acetylation by a bacterial N-
acetyltransferase during expression, the (His)6-tag was cleaved
with thrombin to give hARD1 with an N-terminal sequence of
GSHMNIRNARP, with the ﬁrst three residues (underlined)
being derived from the vector. The resulting GSH-hARD1
was incubated with [1-14C]-AcCoA and controls were run with
several proteins that contained a glycine residue at the N-ter-
minus, under the same conditions as those used for hARD1
and HIF-1a substrates. The control proteins were FIH [9],
HIF530–698, open reading frames 2 [23], 15 and 16 from the
clavulanic acid biosynthesis pathway, (unpublished data) and
phytanoyl coenzyme A hydroxylase [24]. Autoradiographic
analysis revealed that the band corresponding to GSH-hARD1
was [14C]-labeled, suggesting that the acetylation was indeed
self-mediated; a faint band corresponding to acetylated resid-
ual (His)6-tagged hARD1 was also visible in assays containing
enzyme with both [1-14C]-AcCoA and ORFs 2, 15 and 16
(Fig. 5). The site of acetylation on the AcCoA-incubated
hARD1 was identiﬁed as the N-terminus by incubating
GSH-hARD1 with AcCoA, followed by tryptic digest/mass
spectrometry as before. A +42 Da shift was observed on the
peptide derived from the N-terminus of the GSH-hARD1.
The identity of the N-terminal peptide and location of acetyla-
tion site was conﬁrmed by MS/MS analysis. In the absence of
AcCoA the N-terminal peptide showed no evidence of acetyla-
tion (data not shown). In none of the LC/MS analyses was any
evidence accrued for side-chain acetylation of any of the 16 ly-
sine residues of hARD1 (lysines 29, 51, 59, 78, 89, 105, 113,
136, 148, 165, 167, 179, 183, 198, 210, 225). The extent of
hARD1 acetylation as a function of pH was studied in the
range 5–11 using (His)6-tagged hARD1; incubations at higher
pHs showed a higher level of incorporation of [14C]-label
(Fig. 6), consistent with N-terminal amine acetylation.
After observation of the self-mediated N-terminal acetyla-
tion of unnatural residues on hARD1 the question of whether
hARD1 may self-acetylate its natural N-terminus arose. Wild-
Fig. 2. LC/MS analyses of the incubation of (His)6-tagged hARD1 with HIF-1a504–553 and AcCoA. (A) HPLC trace from incubation of (His)6-
tagged hARD1 with HIF-1a504–553 and AcCoA, (B) without (His)6-tagged hARD1. MS data resulting from peaks in A and B, respectively, are shown
in C and D. The peak at 1082 Da corresponds to the [M + 7H]7+ charge state of HIF-1a504–553.
1914 T.A. Murray-Rust et al. / FEBS Letters 580 (2006) 1911–1918type hARD1 was produced in E. coli and the crude extract was
incubated with either AcCoA, and analysed by SDS–PAGE,
tryptic digestion and LC/MS, or [1-14C]-AcCoA, and thenautoradiographed. However, neither technique provided any
evidence that the natural N-terminus of hARD1 was function-
ing as a substrate for self-acetylation (data not shown).
Fig. 3A. Autoradiograph from the incubations of (His)6-tagged
hARD1 with [1-14C]-AcCoA and HIF-1a504–553. The arrowed band
corresponds to acetylated (His)6-tagged hARD1. H2A = Histone Type
II A; there was no evidence for (His)6-tagged hARD1-mediated histone
acetylation as labeling of the H2A occurred in the absence of (His)6-
tagged ARD1.
Fig. 3B. Autoradiograph from the incubations of (His)6-tagged
hARD1 with [1-14C]-AcCoA and partially puriﬁed GST-tagged HIF-
1a401–603. The arrowed band corresponds to acetylated (His)6-tagged
hARD1.
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Jeong et al. identiﬁed mARD1 as a protein that aﬀected the
stability of HIF-1a via a luciferase based reporter system uti-
lizing pSV40promoter-EpoHRE-Luc (HRE = hypoxic re-
sponse element) and mutated EpoHRE-Luc reporters [15].
Using an HRE-containing VEGF gene it was observed that
an increase in VEGF mRNA production under hypoxia was
abrogated in HT1080 cells overexpressing mARD1, implying
hARD1 activated the HIF system. It was reported that recom-
binant mouse ARD1 (mARD1; 96% sequence identity with
hARD1) produced using the pET28a vector catalysed the
transfer of an acetyl group from AcCoA to the side-chain of
a fragment of recombinant human HIF-1a corresponding to
residues 401–603. The evidence for acetylation of the fragment
was in part based upon [14C]-autoradiography using [1–14C]-
AcCoA and Western blot analysis using anti-N-acetyl Lys
antibodies. Western blot analyses of incubations with recombi-
nant mARD1 and six lysine to arginine mutations of a HIF-
1a401–603 fragment led to the initial assignment of Lys532 as
the site of acetylation; support for the assignment came from
isolation of acetylated HIF-1a by immunoprecipitation with
anti-N-acetyl-Lys antibody and V8 protease-mediated diges-tion followed by analysis by MALDI-MS. A species with a
mass of 1580.75 Da, corresponding to that predicted for the
acetylated HIF525–537 fragment (including with oxidation of a
single methionine to a sulfoxide, and which contained no other
lysine residues) was observed, leading to identiﬁcation of the
acetylation site as Lys532. However, no MS/MS data was re-
ported in this study.
Recently it has been reported that hARD1 does not aﬀect
the stability of HIF-1a and that hARD1 is not induced by hy-
poxia [20,21]. Fisher et al. used a retroviral vector to deliver
hARD1 shRNA into HepG2 cells to knock down hARD1
message by >80%, and observed a resultant decrease in VEGF
and EPO levels, in accordance with the earlier results of Jeong
et al. However, they did not notice a decrease in the levels of
HIF-1a protein, implying that knockout of hARD1 message
was decreasing VEGF and EPO protein levels by a non-
HIF-1a-mediated process. Bilton et al. also studied the eﬀect
of hARD1 on HIF-1a and -2a levels in HeLa and HT1080
cells by both overexpressing and silencing hARD1 [21]. When
hARD1 was overexpressed as a tagged fusion protein in HeLa
cells in both normoxia and hypoxia for 4 and 8 h no diﬀerence
in HIF-1a levels between the control and the hARD1 over-
expressing cells was observed. It was also observed that when
hARD1 was silenced, there was no resultant stabilization in
HIF-1a at the protein level. This observation contrasts with
the fact that silencing of PHD2, known to mediate hydroxyl-
ation-dependent destruction of HIF-1a, strongly increases
HIF-1a stability [21,25].
We investigated the acetyltransferase activity of highly puri-
ﬁed hARD1 using the HIF-1a504–553 fragment via LC/MS and
[14C]-autoradiography employing [1-14C]-AcCoA. We did not
observe either a mass shift consistent with acetylation of the
putative HIF-1a substrate, nor incorporation of any [14C] into
the HIF fragment. After this we used a larger fragment of
HIF-1a, corresponding to residues 401–603 and containing
the whole of the C-terminal oxygen dependent degradation do-
main, in an attempt to detect any acetylation using [14C]-auto-
radiography, but we were not able to conﬁrm the results of
Jeong et al [15]. Thus, with respect to the HIF system our re-
sults imply that hARD1 does not, at least solely, catalyse acet-
ylation of the amino side-chain of Lys532 of HIF-1a.
During [14C]-autoradiography studies using (His)6-tagged
hARD1 a radioactive band corresponding to hARD1 was ob-
served, which was consistent with incorporation of a [14C]-la-
beled acetyl group. ESI-MS analyses also revealed that
recombinant hARD1, with an unnatural N-terminus, pro-
duced in E. coli had undergone partial acetylation. Although
it cannot be certain that all the acetylation of hARD1 occur-
ring within E. coli is autocatalytic, subsequent experiments
using LC/MS and tryptic digestion with LC/MS/MS demon-
strated that recombinant hARD1 can catalyse slow self-acety-
lation at its N-terminus, but not, under the assay conditions, at
the side-chains of any of the 16 lysine residues that it contains.
The reaction was found to occur most eﬃciently at high pH
consistent with a process involving solvent-mediated deproto-
nation of the N-terminal amino group. Acetylation at the N-
terminus was observed for two diﬀerent sequences [GSSHH-
for (His)6-tagged and GSHMN- for thrombin-cleaved
hARD1] but not for the natural N-terminus of hARD1
(MNIRNARPED). These observations are consistent with
the known selectivity of the yeast NatA complex, which can
accept N-terminal serinyl-, glycyl-, alaninyl- and threoninyl-
Fig. 4. MS/MS spectra of the (His)6-tagged hARD1 N-terminal tryptic peptide, GSSHHHHHHSSGLVPR, (A) in the absence of AcCoA
([M + 3H]3+ = 590.4) and (B) in the presence of AcCoA ([M + 3H]3+ = 604.3). The presence of a b-ion series from b2 to b6 in both spectra formally
assigns the site of acetylation to the ﬁrst two N-terminal amino acid residues.
Fig. 5. Autoradiograph showing incubations of cleaved hARD1 (lanes 1–2, 4–5 and 7–8) with [1-14C]-AcCoA and ORFs 2, 15 and 16 (lanes 2–3, 5–6
and 8–9) from the clavulanic acid biosynthesis pathway as control proteins with glycyl residues at their N-termini. A faint band corresponding to
residual (His)6-tagged hARD1 is visible above the cleaved hARD1.
1916 T.A. Murray-Rust et al. / FEBS Letters 580 (2006) 1911–1918residues as substrates for Na-acetylation, and suggest that,
whilst it cannot be ruled out, there is no evidence that N-termi-
nal acetylation of hARD1 occurs in human cells [19]. Giventhat N-terminal Met, Asn or Val (as in some homologues) res-
idues are not reported to be substrates for the NatA complex,
(for review, see [26]) it is possible that wild-type hARD1 and
Fig. 6. [14C]-Autoradiograph of incubations of (His)6-tagged hARD1
with [1-14C]-AcCoA at diﬀerent pH values in the range 5–11.
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be refractory to self-N-acetylation.
Although Jeong et al. [15] reported that addition of NATH
(also known as Tubedown-100) to murine ARD1 did not aﬀect
the acetylation of HIF-1a, a complex between hARD1 and
NATH has been observed and found to possess N-terminal
acetyltransferase activity with peptide substrates, consistent
with observations for the yeast enzyme [18]. Thus, Arnesen
et al. noted that mammalian ARD1 appears to be a novel ace-
tyltransferase that was capable of both Na- and Ne-protein
acetylation, in complex with NAT and alone, respectively. Ta-
ken together with other recent studies on cells from Bilton
et al. [21] and Fisher et al. [20] the work described here with
puriﬁed proteins implies that hARD1 does not, at least alone,
catalyse the acetylation of Lys532 of human HIF-1a and as a
consequence is likely not directly involved in its regulation,
at least via a Lys532 acetylation-mediated process. The avail-
able evidence indicated that hARD1 is in fact a more typical
component of a heterodimeric complex with NATH that catal-
yses N-terminal acetylation reactions. The mechanism by
which this, or other activity, of hARD1 aﬀects levels of the
biomedicinally important proteins EPO and VEGF is there-
fore unclear, and is a direction for further study of hARD1.Note added in proof
Recently, Arnesen et al. [27] have reported evidence that the
stability of HIF-1a is not regulated by hARD1 and that the
level of hARD1 is not hypoxically regulated. These authors
also reported evidence that hARD1 does not acetylate HIF-
1a, but importantly did demonstrate an interaction between
hARD1 and HIF-1a.
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